MiMedx Group (NASDAQ:MDXG) Downgraded to “Buy” at StockNews.com

StockNews.com downgraded shares of MiMedx Group (NASDAQ:MDXG) from a strong-buy rating to a buy rating in a research note issued to investors on Monday.

A number of other research firms have also recently issued reports on MDXG. Craig Hallum cut their price target on MiMedx Group from $14.00 to $12.00 and set a buy rating for the company in a report on Thursday, August 1st. HC Wainwright reaffirmed a buy rating and issued a $11.00 target price on shares of MiMedx Group in a research note on Wednesday, May 1st. Finally, Cantor Fitzgerald reissued an overweight rating and set a $11.00 price target on shares of MiMedx Group in a research note on Thursday, August 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of Buy and a consensus price target of $12.00.

MiMedx Group Price Performance

MDXG traded up $0.13 during trading on Monday, hitting $6.38. The company’s stock had a trading volume of 817,008 shares, compared to its average volume of 764,297. The company has a quick ratio of 2.71, a current ratio of 3.85 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $941.71 million, a price-to-earnings ratio of 14.20 and a beta of 1.98. The firm’s 50 day moving average price is $7.06 and its two-hundred day moving average price is $7.41. MiMedx Group has a 12 month low of $5.57 and a 12 month high of $9.27.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. AJOVista LLC acquired a new position in MiMedx Group in the fourth quarter valued at approximately $25,000. Headlands Technologies LLC acquired a new position in shares of MiMedx Group in the 1st quarter valued at $27,000. Loudon Investment Management LLC bought a new position in shares of MiMedx Group in the 4th quarter worth $105,000. Entropy Technologies LP acquired a new stake in shares of MiMedx Group during the first quarter worth $99,000. Finally, Raymond James & Associates acquired a new stake in shares of MiMedx Group during the fourth quarter worth $114,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.